China-based biopharmaceutical company RiboX Therapeutics Ltd. announced on Sunday that it has dosed the first patient in its first-in-human (FIH) Phase I/IIa clinical trial (SPRINX-1) evaluating the safety and efficacy of RXRG001.

RXRG001 is claimed to be the first-ever circular RNA therapy to receive FDA IND approval and is intended for the treatment of radiation-induced xerostomia and hyposalivation.

Principal Investigator, Henry T Hoffman, MD, MS, FACS, professor, Otolaryngology and editor, Iowa Head and Neck Protocols of University of Iowa, said, 'Patients suffering radiation-induced xerostomia face a need for new therapeutic options. RXRG001 introduces an innovative approach offering hope for my patients. We are proud to be the first site to treat a patient with RXRG001 and look forward to continuing to collaborate with RiboX and other investigative centres to rapidly enrol patients in this FIH trial. I am glad that our first patient is tolerating the investigational product well.'